From AI X-Rays to Ultra-Short Drug Regimens: 2025’s Tuberculosis Breakthroughs
A sweeping 2025 review documents major advances in tuberculosis diagnostics, shorter all-oral drug regimens, novel compounds, vaccines, and disease reclassification, ...
A sweeping 2025 review documents major advances in tuberculosis diagnostics, shorter all-oral drug regimens, novel compounds, vaccines, and disease reclassification, ...
A cross-sectional study of 620 older adults with latent tuberculosis infection in Huzhou, China, found that 69.35% accepted tuberculosis preventive ...
Pulmonary tuberculosis remains one of the world's most stubborn infectious diseases, and a central challenge for clinicians is telling apart ...
A scoping review of 13 studies covering 24,652 participants reveals both progress and persistent structural barriers in Angola's fight against ...
Tuberculosis remains one of the world's deadliest infectious diseases, killing an estimated 1.23 million people in 2024 out of 10.7 ...
A new study reveals that the MarR family regulator AcasR controls mycobacterial susceptibility to the anti-tuberculosis compound ACA by repressing ...
A new review proposes that micronutrient deficiencies, thyroid dysfunction, and impaired antimycobacterial immunity form a self-perpetuating cycle that may shape ...
Nigeria's first sequencing-based surveillance program for drug-resistant tuberculosis uncovered rifampicin and isoniazid resistance missed by routine drug susceptibility tests, demonstrating ...
Researchers screened more than 87,000 compounds against the essential interaction between the tuberculosis bacterium's RNA polymerase and the transcription factor ...
Computational screening of four halogenated quinoline derivatives identifies QNL1 and QNL3 as promising oral drug candidates against tuberculosis, E. coli, ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine